ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

Agios Pharmaceuticals Inc

AGIO · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.

ESG Overview

Overall: BBB (High)
E: AS: BBG: BB

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $28.58 +0.05 (+0.18%)
Market Cap$1.63B
P/E Ratio—
EPS$—
52W High$46.00
52W Low$22.24
Beta0.88

Data from Finnhub · Updated Mar 10, 2026

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.